Literature DB >> 8333474

Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse.

I B Vergote1, J Kaern, V M Abeler, E O Pettersen, L N De Vos, C G Tropé.   

Abstract

OBJECTIVES: Our purpose was to identify prognostic factors in stage I epithelial invasive ovarian carcinoma. STUDY
DESIGN: The traditional clinical and pathologic prognostic variables and deoxyribonucleic acid ploidy were analyzed in a group of 290 patients.
RESULTS: A multivariate analysis identified degree of differentiation as the most powerful prognostic indicator of disease-free survival, followed by deoxyribonucleic acid ploidy and, finally, International Federation of Gynecology and Obstetrics (1986) stage. Tumors with clear cell carcinoma elements were not graded, and in this subgroup International Federation of Gynecology and Obstetrics (1986) stage was the most important prognostic characteristic. When the effects of the three most important factors were accounted for in graded tumors, then none of the following were prognostic: histologic type, dense adhesion, extracapsular growth, ascites, rupture during surgery, International Federation of Gynecology and Obstetrics (1973) stage, size of tumor, and age and type of adjuvant treatment. None of 77 patients with well differentiated deoxyribonucleic acid diploid tumors had relapses.
CONCLUSION: Deoxyribonucleic acid ploidy is an important new independent prognostic factor in stage I ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8333474     DOI: 10.1016/0002-9378(93)90129-7

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  15 in total

1.  The diagnostic "gold standard" in oncology: increasing importance and increasing concerns.

Authors:  Maurie Markman
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

Review 2.  Pursuit of optimum outcomes in ovarian cancer: methodological approaches to therapy.

Authors:  D D Gibbs; M E Gore
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome.

Authors:  C Gamallo; J Palacios; G Moreno; J Calvo de Mora; A Suárez; A Armas
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

4.  Multivariate analyses of DNA index, p62c-myc, and clinicopathological status of patients with ovarian cancer.

Authors:  M Curling; S Stenning; C N Hudson; J V Watson
Journal:  J Clin Pathol       Date:  1998-06       Impact factor: 3.411

Review 5.  Early ovarian cancer.

Authors:  G Coukos; S C Rubin
Journal:  Curr Treat Options Oncol       Date:  2000-06

Review 6.  Pharmaceutical management of ovarian cancer : current status.

Authors:  Maurie Markman
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation.

Authors:  A Paju; T Sorsa; T Tervahartiala; E Koivunen; C Haglund; A Leminen; T Wahlström; T Salo; U H Stenman
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

8.  Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer.

Authors:  Supachai Raungkaewmanee; Siriwan Tangjitgamol; Sumonmal Manusirivithaya; Sunamchok Srijaipracharoen; Thaovalai Thavaramara
Journal:  J Gynecol Oncol       Date:  2012-09-19       Impact factor: 4.401

9.  Prognostic factors in early-stage ovarian cancer.

Authors:  Germana Tognon; Mario Carnazza; Monica Ragnoli; Stefano Calza; Federico Ferrari; Angela Gambino; Valentina Zizioli; Sara Notaro; Benedetta Sostegni; Enrico Sartori
Journal:  Ecancermedicalscience       Date:  2013-06-13

10.  TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival.

Authors:  Y Wang; A Helland; R Holm; H Skomedal; V M Abeler; H E Danielsen; C G Tropé; A-L Børresen-Dale; G B Kristensen
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.